Literature DB >> 30554174

Preoperative stereotactic radiosurgery before planned resection of brain metastases: updated analysis of efficacy and toxicity of a novel treatment paradigm.

Roshan S Prabhu1,2, Katherine R Miller1, Anthony L Asher1,3, John H Heinzerling1,2, Benjamin J Moeller1,2, Scott P Lankford1,2, Robert J McCammon1,2, Carolina E Fasola1,2, Kirtesh R Patel4, Robert H Press5, Ashley L Sumrall1, Matthew C Ward1,2, Stuart H Burri1,2.   

Abstract

OBJECTIVEPreoperative stereotactic radiosurgery (SRS) is a feasible alternative to postoperative SRS and may lower the risk of radiation necrosis (RN) and leptomeningeal disease (LMD) recurrence. The study goal was to report the efficacy and toxicity of preoperative SRS in an expanded patient cohort with longer follow-up period relative to prior reports.METHODSThe records for patients with brain metastases treated with preoperative SRS and planned resection were reviewed. Patients with classically radiosensitive tumors, planned adjuvant whole brain radiotherapy, or no cranial imaging at least 1 month after surgery were excluded. Preoperative SRS dose was based on lesion size and was reduced approximately 10-20% from standard dosing. Surgery generally followed within 48 hours.RESULTSThe study cohort consisted of 117 patients with 125 lesions treated with single-fraction preoperative SRS and planned resection. Of the 117 patients, 24 patients were enrolled in an initial prospective trial; the remaining 93 cases were consecutively treated patients who were retrospectively reviewed. Most patients had a single brain metastasis (70.1%); 42.7% had non-small cell lung cancer, 18.8% had breast cancer, 15.4% had melanoma, and 11.1% had renal cell carcinoma. Gross total resection was performed in 95.2% of lesions. The median time from SRS to surgery was 2 days, the median SRS dose was 15 Gy, and the median gross tumor volume was 8.3 cm3. Event cumulative incidence at 2 years was as follows: cavity local recurrence (LR), 25.1%; distant brain failure, 60.2%; LMD, 4.3%; and symptomatic RN, 4.8%. The median overall survival (OS) and 2-year OS rate were 17.2 months and 36.7%, respectively. Subtotal resection (STR, n = 6) was significantly associated with increased risk of cavity LR (hazard ratio [HR] 6.67, p = 0.008) and worsened OS (HR 2.63, p = 0.05) in multivariable analyses.CONCLUSIONSThis expanded and updated analysis confirms that single-fraction preoperative SRS confers excellent cavity local control with very low risk of RN or LMD. Preoperative SRS has several potential advantages compared to postoperative SRS, including reduced risk of RN due to smaller irradiated volume without need for cavity margin expansion and reduced risk of LMD due to sterilization of tumor cells prior to spillage at the time of surgery. Subtotal resection, though infrequent, is associated with significantly worse cavity LR and OS. Based on these results, a randomized trial of preoperative versus postoperative SRS is being designed.

Entities:  

Keywords:  DBF = distant brain failure; GPA = graded prognostic index; GTR = gross-total resection; GTV = gross tumor volume; HR = hazard ratio; IQR = interquartile range; LMD = leptomeningeal disease; LR = local recurrence; NSCLC = non–small cell lung cancer; OS = overall survival; RCC = renal cell carcinoma; RN = radiation necrosis; RT = radiotherapy; SRS = stereotactic radiosurgery; STR = subtotal resection; WBRT = whole-brain RT; brain metastases; leptomeningeal disease; neurosurgery; oncology; radiotherapy; stereotactic radiosurgery

Year:  2018        PMID: 30554174     DOI: 10.3171/2018.7.JNS181293

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Neoadjuvant Stereotactic Radiosurgery: a Further Evolution in the Management of Brain Metastases.

Authors:  Cristian Udovicich; Claire Phillips; David L Kok; Damien Tange; Nikki M Plumridge; Roshan S Prabhu; Neda Haghighi
Journal:  Curr Oncol Rep       Date:  2019-07-04       Impact factor: 5.075

2.  [Surgical treatment and radiation therapy of brain metastases].

Authors:  Jan P Boström; Kathleen Jetschke; Kirsten Schmieder; Irenä Us A Adamietz
Journal:  Radiologe       Date:  2021-07-16       Impact factor: 0.635

3.  Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection-Outcome, Prognostic Factors, and Recurrence Patterns.

Authors:  Rami A El Shafie; Thorsten Dresel; Dorothea Weber; Daniela Schmitt; Kristin Lang; Laila König; Simon Höne; Tobias Forster; Bastian von Nettelbladt; Tanja Eichkorn; Sebastian Adeberg; Jürgen Debus; Stefan Rieken; Denise Bernhardt
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

Review 4.  Operative and peri-operative considerations in the management of brain metastasis.

Authors:  Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

Review 5.  Current status and recent advances in resection cavity irradiation of brain metastases.

Authors:  Giuseppe Minniti; Maximilian Niyazi; Nicolaus Andratschke; Matthias Guckenberger; Joshua D Palmer; Helen A Shih; Simon S Lo; Scott Soltys; Ivana Russo; Paul D Brown; Claus Belka
Journal:  Radiat Oncol       Date:  2021-04-15       Impact factor: 3.481

6.  Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery.

Authors:  Achiraya Teyateeti; Paul D Brown; Anita Mahajan; Nadia N Laack; Bruce E Pollock
Journal:  Neurooncol Adv       Date:  2021-03-02

7.  Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements.

Authors:  Sarah C Brüningk; Jeffrey Peacock; Christopher J Whelan; Renee Brady-Nicholls; Hsiang-Hsuan M Yu; Solmaz Sahebjam; Heiko Enderling
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

8.  Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection of brain metastasis: a case series of 20 patients.

Authors:  Shoichi Deguchi; Koichi Mitsuya; Kazuaki Yasui; Keisuke Kimura; Tsuyoshi Onoe; Hirofumi Ogawa; Hirofumi Asakura; Hideyuki Harada; Nakamasa Hayashi
Journal:  Int J Clin Oncol       Date:  2021-11-18       Impact factor: 3.402

Review 9.  Management Strategies for Large Brain Metastases.

Authors:  Nehaw Sarmey; Tehila Kaisman-Elbaz; Alireza M Mohammadi
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

Review 10.  The management of elderly patients with brain metastases from breast cancer.

Authors:  Henry Ruiz-Garcia; Lina Marenco-Hillembrand; Jennifer L Peterson; Katherine Tzou; Timothy D Malouff; Kaisorn L Chaichana; Daniel M Trifiletti; Laura Vallow
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.